Nadolol (tablet): Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
'''''For patient information, click | '''''For patient information about Nadolol, click [[Nadolol (patient information)|here]].''''' | ||
{{SB}} CORGARD<sup>®</sup> | {{SB}} CORGARD<sup>®</sup> | ||
==Overview== | ==Overview== | ||
==Category== | ==Category== | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
====CORGARD (nadolol) tablet==== | |||
''' [[Nadolol indications and usage|Indications and Usage]]''' | ''' [[Nadolol indications and usage|Indications and Usage]]''' | ||
Revision as of 02:44, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information about Nadolol, click here.
Synonyms / Brand Names: CORGARD®
Overview
Category
FDA Package Insert
CORGARD (nadolol) tablet
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages